Cowen Downgrades Merrimack Pharmaceuticals (MACK) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Merrimack Pharma (MACK) Misses Q2 EPS by 7c
August 4, 2016 4:13 PM EDTMerrimack Pharma (NASDAQ: MACK) reported Q2 EPS of ($0.40), $0.07 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $33.7 million versus the consensus estimate of $30.97 million.
Financial Outlook
In an effort to provide... More
